Skip to main content
ANAB logo

AnaptysBio, Inc.

ANABNASDAQHealthcareBiotechnology

$50.50Today:- (-)1Y +41.47%

As of Oct 28, 2026 close

Market cap
$1.82B
P/E (TTM)
9.28
Forward P/E
-
Dividend yield
-
52-week range
$30.27$73.30
Volume (live)
-
Avg. volume (3M)
560.81K

AnaptysBio (ANAB) Cash Flow Statement

In fiscal 2026 (fiscal year ended Jun 30, 2026), AnaptysBio used $105.12M of cash in operating activities. Free cash flow was −$105.12M.

AnaptysBio Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AnaptysBio, Inc. (ANAB) - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 2026Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income--13.23-145.23-163.62-128.72-57.80-19.93-97.34-61.66-30.07
Depreciation & Amortization-0.560.612.380.682.091.620.510.320.18
Deferred Income Tax-0.000.000.000.000.000.000.00-1.231.38
Stock Based Compensation16.643.777.2233.2127.3615.3511.5012.419.964.38
Change in Working Capital--80.53-66.33-0.326.84-7.49-7.8316.853.464.08
Change in Accounts Receivable-6.92-33.91-5.43-0.54-0.880.000.171.431.23
Change in Inventory-0.000.000.000.000.000.000.000.00-237.97
Change in Accounts Payable--87.33-33.8410.949.70-4.74-7.690.007.082.22
Change in Other Working Capital--87.64-32.4118.087.38-1.87-0.1416.68-3.62238.61
Other Operating Activities-77.0241.5718.0820.261.930.49-1.960.650.62
Net Cash from Operating Activities-105.1219.70-135.34-120.80-73.59-45.92-14.16-69.52-48.51-19.44
Investing Activities
Capital Expenditures--0.09-0.36-0.81-0.36-1.37-0.57-0.81-1.06-0.29
Acquisitions-0.000.000.00394.490.000.000.00347.54290.91
Purchases of Investments--196.41-380.38-303.92-802.50-118.6695.04-251.82-347.54-290.91
Sales/Maturities of Investments-424.53476.13449.48408.02158.85289.97384.05206.1548.14
Other Investing Activities--0.09-0.360.00-394.490.020.000.00-347.54-290.91
Net Cash from Investing Activities85.09228.0331.36144.75-394.8538.8494.48131.43-142.45-243.06
Financing Activities
Debt Repayment--76.80-15.23-11.73-2.470.00-1.38-7.50-6.880.00
Common Stock Issued-14.26100.842.4711.832.550.503.01227.48292.54
Common Stock Repurchased--70.08-7.96-50.000.000.000.000.000.000.00
Other Financing Activities-239.45-78.2526.67-11.7732.19249.750.000.002.76-0.08
Net Cash from Financing Activities-188.71-132.61127.05-59.3044.02252.30-0.88-4.49223.36292.45
Summary
Net Change in Cash-208.74115.1223.08-35.34-424.42245.2179.4457.4232.4129.96
Cash at Beginning of Period-23.0835.9771.31495.73250.52171.02113.6081.2551.29
Cash at End of Period-138.2023.0835.9771.31495.73250.46171.02113.6681.25
Free Cash Flow-105.1219.70-135.34-121.61-73.95-47.29-14.73-70.32-49.57-19.73
Supplemental Disclosures
Interest Paid------0.00---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AnaptysBio Cash Flow

What is AnaptysBio's free cash flow?

AnaptysBio had negative free cash flow of $105.12M in fiscal 2026 (fiscal year ended Jun 30, 2026).

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition